Cheetah™ Life Sciences gives you access to practical resources and professional references on everything from maintaining full compliance in all areas of food, drug and cosmetics regulation to the rapidly shifting area of medical device regulation. Given the ever-changing regulatory environment, it’s crucial to have access to current and reliable resources that cover the issues of greatest concern. Using Cheetah™ Life Sciences helps you make the correct choices, maintain compliance, establish effective policies
The industry’s leading professionals deliver expert explanations, citations, and annotations covering every key area of life science law, in addition to full text of all laws and regulations.
The FDA Reform Navigator Smart Chart allows users to create a customizable chart of any provision of the FDA Food Safety Modernization Act including summaries of each provision.
Regular updates, reporters, and newsletters keep life science attorneys and professionals completely current on all key developments.
Explore the types of articles and in-depth analysis available through the Health Law Daily.
Audit finds estimated $22 Million in Medicare overpayments to Indiana hospital
An Indiana hospital disagrees with an OIG review finding that it was noncompliant with Medicare billing requirements and billed for stays that did not meet the higher acute inpatient rehabilitation...
CMS made $19.9 million in overpayments for double billed ambulance services
A review of Medicare Part B payments found that Medicare was often billed by skilled nursing facilities under the Part A consolidated billing and by ambulance suppliers under Part B for the same...
Consumer pet food concerns lack bite, court calls them ‘true and irrelevant’
Claims that pet food contained lead, arsenic, cadmium, and mercury did not survive a manufacturer’s summary judgement motion because the consumer failed to provide evidence of harm.
Allegedly inadequate warnings not cause of patient’s injury
Surgeon’s continued use of the product undermined the patient’s allegations, even though the patient needed a full revision surgery with a different implant system.
False claims lawsuit alleging cancer drug scheme survives dismissal attempt
Qui tam suit can proceed against McKesson and another distributor for purported role in prefilled syringe program but first-to-file bar and statute of limitations halt claims against subsidiaries.